308 related articles for article (PubMed ID: 36629855)
1. Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties.
Svilenov HL; Arosio P; Menzen T; Tessier P; Sormanni P
MAbs; 2023; 15(1):2164459. PubMed ID: 36629855
[TBL] [Abstract][Full Text] [Related]
2. Predicting Antibody Developability Profiles Through Early Stage Discovery Screening.
Bailly M; Mieczkowski C; Juan V; Metwally E; Tomazela D; Baker J; Uchida M; Kofman E; Raoufi F; Motlagh S; Yu Y; Park J; Raghava S; Welsh J; Rauscher M; Raghunathan G; Hsieh M; Chen YL; Nguyen HT; Nguyen N; Cipriano D; Fayadat-Dilman L
MAbs; 2020; 12(1):1743053. PubMed ID: 32249670
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in silico assessment of the developability of a designed monoclonal antibody library.
Wolf Pérez AM; Sormanni P; Andersen JS; Sakhnini LI; Rodriguez-Leon I; Bjelke JR; Gajhede AJ; De Maria L; Otzen DE; Vendruscolo M; Lorenzen N
MAbs; 2019; 11(2):388-400. PubMed ID: 30523762
[TBL] [Abstract][Full Text] [Related]
4. Biophysical properties of the clinical-stage antibody landscape.
Jain T; Sun T; Durand S; Hall A; Houston NR; Nett JH; Sharkey B; Bobrowicz B; Caffry I; Yu Y; Cao Y; Lynaugh H; Brown M; Baruah H; Gray LT; Krauland EM; Xu Y; Vásquez M; Wittrup KD
Proc Natl Acad Sci U S A; 2017 Jan; 114(5):944-949. PubMed ID: 28096333
[TBL] [Abstract][Full Text] [Related]
5. Assessing developability early in the discovery process for novel biologics.
Fernández-Quintero ML; Ljungars A; Waibl F; Greiff V; Andersen JT; Gjølberg TT; Jenkins TP; Voldborg BG; Grav LM; Kumar S; Georges G; Kettenberger H; Liedl KR; Tessier PM; McCafferty J; Laustsen AH
MAbs; 2023; 15(1):2171248. PubMed ID: 36823021
[TBL] [Abstract][Full Text] [Related]
6. Structure-Based Optimization of Antibody-Based Biotherapeutics for Improved Developability: A Practical Guide for Molecular Modelers.
Thorsteinson N; Comeau SR; Kumar S
Methods Mol Biol; 2023; 2552():219-235. PubMed ID: 36346594
[TBL] [Abstract][Full Text] [Related]
7. Deamidation and isomerization liability analysis of 131 clinical-stage antibodies.
Lu X; Nobrega RP; Lynaugh H; Jain T; Barlow K; Boland T; Sivasubramanian A; Vásquez M; Xu Y
MAbs; 2019 Jan; 11(1):45-57. PubMed ID: 30526254
[TBL] [Abstract][Full Text] [Related]
8. Developability assessment during the selection of novel therapeutic antibodies.
Jarasch A; Koll H; Regula JT; Bader M; Papadimitriou A; Kettenberger H
J Pharm Sci; 2015 Jun; 104(6):1885-1898. PubMed ID: 25821140
[TBL] [Abstract][Full Text] [Related]
9. Discovery-stage identification of drug-like antibodies using emerging experimental and computational methods.
Makowski EK; Wu L; Gupta P; Tessier PM
MAbs; 2021; 13(1):1895540. PubMed ID: 34313532
[TBL] [Abstract][Full Text] [Related]
10. Current advances in biopharmaceutical informatics: guidelines, impact and challenges in the computational developability assessment of antibody therapeutics.
Khetan R; Curtis R; Deane CM; Hadsund JT; Kar U; Krawczyk K; Kuroda D; Robinson SA; Sormanni P; Tsumoto K; Warwicker J; Martin ACR
MAbs; 2022; 14(1):2020082. PubMed ID: 35104168
[TBL] [Abstract][Full Text] [Related]
11. Developability assessment for monoclonal antibody drug candidates: a case study.
Garripelli VK; Wu Z; Gupta S
Pharm Dev Technol; 2021 Jan; 26(1):11-20. PubMed ID: 32986499
[TBL] [Abstract][Full Text] [Related]
12. Advancing Therapeutic Protein Discovery and Development through Comprehensive Computational and Biophysical Characterization.
Gentiluomo L; Svilenov HL; Augustijn D; El Bialy I; Greco ML; Kulakova A; Indrakumar S; Mahapatra S; Morales MM; Pohl C; Roche A; Tosstorff A; Curtis R; Derrick JP; Nørgaard A; Khan TA; Peters GHJ; Pluen A; Rinnan Å; Streicher WW; van der Walle CF; Uddin S; Winter G; Roessner D; Harris P; Frieß W
Mol Pharm; 2020 Feb; 17(2):426-440. PubMed ID: 31790599
[TBL] [Abstract][Full Text] [Related]
13. High-throughput screening for developability during early-stage antibody discovery using self-interaction nanoparticle spectroscopy.
Liu Y; Caffry I; Wu J; Geng SB; Jain T; Sun T; Reid F; Cao Y; Estep P; Yu Y; Vásquez M; Tessier PM; Xu Y
MAbs; 2014; 6(2):483-92. PubMed ID: 24492294
[TBL] [Abstract][Full Text] [Related]
14. Biophysical and Sequence-Based Methods for Identifying Monovalent and Bivalent Antibodies with High Colloidal Stability.
Alam ME; Geng SB; Bender C; Ludwig SD; Linden L; Hoet R; Tessier PM
Mol Pharm; 2018 Jan; 15(1):150-163. PubMed ID: 29154550
[TBL] [Abstract][Full Text] [Related]
15. Developability assessment at early-stage discovery to enable development of antibody-derived therapeutics.
Zhang W; Wang H; Feng N; Li Y; Gu J; Wang Z
Antib Ther; 2023 Jan; 6(1):13-29. PubMed ID: 36683767
[TBL] [Abstract][Full Text] [Related]
16. Ultradilute Measurements of Self-Association for the Identification of Antibodies with Favorable High-Concentration Solution Properties.
Starr CG; Makowski EK; Wu L; Berg B; Kingsbury JS; Gokarn YR; Tessier PM
Mol Pharm; 2021 Jul; 18(7):2744-2753. PubMed ID: 34105965
[TBL] [Abstract][Full Text] [Related]
17. Developability studies before initiation of process development: improving manufacturability of monoclonal antibodies.
Yang X; Xu W; Dukleska S; Benchaar S; Mengisen S; Antochshuk V; Cheung J; Mann L; Babadjanova Z; Rowand J; Gunawan R; McCampbell A; Beaumont M; Meininger D; Richardson D; Ambrogelly A
MAbs; 2013; 5(5):787-94. PubMed ID: 23883920
[TBL] [Abstract][Full Text] [Related]
18. Five computational developability guidelines for therapeutic antibody profiling.
Raybould MIJ; Marks C; Krawczyk K; Taddese B; Nowak J; Lewis AP; Bujotzek A; Shi J; Deane CM
Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4025-4030. PubMed ID: 30765520
[TBL] [Abstract][Full Text] [Related]
19. Beyond affinity: selection of antibody variants with optimal biophysical properties and reduced immunogenicity from mammalian display libraries.
Dyson MR; Masters E; Pazeraitis D; Perera RL; Syrjanen JL; Surade S; Thorsteinson N; Parthiban K; Jones PC; Sattar M; Wozniak-Knopp G; Rueker F; Leah R; McCafferty J
MAbs; 2020; 12(1):1829335. PubMed ID: 33103593
[TBL] [Abstract][Full Text] [Related]
20. Assessment of Therapeutic Antibody Developability by Combinations of In Vitro and In Silico Methods.
Wolf Pérez AM; Lorenzen N; Vendruscolo M; Sormanni P
Methods Mol Biol; 2022; 2313():57-113. PubMed ID: 34478132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
